Rheumatic manifestations of skin disease
Jennie T. Clarke\textsuperscript{a} and Victoria P. Werth\textsuperscript{b,c}

\textsuperscript{a}Department of Dermatology, Penn State Hershey Medical Center, Hershey, \textsuperscript{b}Philadelphia VA Medical Center, and \textsuperscript{c}Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Correspondence to Victoria P. Werth, MD, Department of Dermatology, Hospital of the University of Pennsylvania, 3600 Spruce Street, 2 Rhoads Pavilion, Philadelphia, PA 19104-4283, USA
Tel: +1 215 893 4308; fax: +1 215 893 5625; e-mail: werth@mail.med.upenn.edu

Current Opinion in Rheumatology 2010, 22:78–84

Purpose of review
There is an increasing interest in improving the understanding of pathophysiology, outcome measures, and therapies of rheumatic skin disease. Increasingly, studies are using the skin as a primary endpoint for evaluating therapies. This will review the current state of the art for the most common rheumatic skin diseases.

Recent findings
A number of medications, including biologics such as tumor necrosis factor α and interferon, have been associated with onset of cutaneous lupus. The cutaneous lupus erythematosus area and severity index has been further validated and utilized in a number of studies. Smoking continues to be associated both with presence and refractoriness of cutaneous lupus erythematosus to therapy. There are several tools now available for evaluating the skin disease of dermatomyositis, but there is a need for new effective therapies. Measurement of skin disease in scleroderma continues to be a challenge, and there is a need for more effective therapies. Several studies show efficacy of intravenous iloprost for severe Raynaud’s and skin ulcers, and of bosentan for digital ulcers.

Summary
The present review covers new outcome measures, treatments, and unusual manifestations of cutaneous lupus, dermatomyositis, scleroderma, and rheumatoid arthritis. There have been a number of new studies related to validation of disease activity measures, as well as their use in evaluation of new therapies for these conditions. Validated outcome measures are required to perform meaningful studies, and will facilitate organized epidemiologic, quality of life, and therapeutic studies.

Keywords
cutaneous lupus erythematosus, dermatomyositis, rheumatoid arthritis, scleroderma

Introduction
Recent advances in the understanding of cutaneous findings in cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE), dermatomyositis, systemic sclerosis (SSc), and rheumatoid arthritis (RA) in terms of clinical evaluation, triggers of disease, outcome measures, systematic clinical studies, and treatment will be discussed.

CLE includes lupus specific and lupus nonspecific skin lesions. Lupus skin lesions include chronic CLE, subacute CLE, and acute CLE [1,2]. Chronic CLE includes localized, generalized, and hypertrophic lupus erythematosus, lupus panniculitis, lupus tumidus, and lupus pernio. The criteria for SLE include four dermatologic criteria, some of which are potentially overlapping. Patients can meet four criteria for SLE based solely on dermatologic findings, and some of these patients are not systematically ill [3]. These criteria include malar rash, photosensitivity, discoid lesions, and oral ulcers. Patients with lupus nonspecific skin lesions are more frequently systemically ill with SLE relative to patients with lupus specific skin lesions [4]. Medications are a frequent trigger of subacute cutaneous lupus erythematosus (SCLE), and the list of drugs that are associated continues to expand. There have not been many systematic studies of CLE [5]. With the development of the Cutaneous Lupus Area and Severity Index (CLASI), a validated outcome measures for CLE, it is hoped that more systematic epidemiologic and therapeutic trials will be performed [6,7].

Skin lesions in dermatomyositis are frequently clinically distinctive, with pathognomonic lesions including Gottron’s papules with lesions targeting over joints, and characteristic lesions including a heliotrope, periungual telangiectasias, dystrophic cuticles, and photo-distributed violaceous erythema. Biopsy of the skin for routine histology frequently looks identical in cutaneous lupus and dermatomyositis.

Cutaneous findings are manifestations important in the classification SSc. Raynaud’s phenomenon may precede the onset of SSc by years, especially in localized
cutaneous SSc (lcSSc). Cutaneous sclerosis typically commences on the distal extremities. Although gradual and often limited to these areas in lcSSc, in diffuse cutaneous SSc (dcSSc), the sclerosis is often preceded by nonpitting edema, rapidly progressive, and more diffuse. Telangiectases are prominent especially on the face. The skin is dry and often pruritic. Areas of hyperpigmentation and hypopigmentation may be seen. Painful digital ulcers arise as a consequence of ischemia.

Cutaneous manifestations of RA include rheumatoid nodules, rheumatoid vasculitis, and granulomatous dermatoses. Patients with RA are at risk of developing psoriasiform cutaneous adverse reactions to tumor necrosis factor α (TNFα) inhibitors.

**Cutaneous lupus erythematosus**

Patients can have skin findings of CLE alone or have CLE associated with underlying systemic disease.

**Cutaneous findings in cutaneous lupus erythematosus**

There have been several recent reports about papulomucinous lupus erythematosus, otherwise termed lupus tumidus, as a subset of chronic cutaneous lupus. Patients with this variant tend to have negative antinuclear antibodies (ANA), increased susceptibility to lesion induction with ultraviolet light, minimal changes at the dermal–epidermal junction on skin biopsy, and they frequently do not have other manifestations of SLE. Rarely these patients have concurrently other forms of CLE, thus suggesting that tumid lupus erythematosus fits, despite many differences from other forms of CLE, in the spectrum of chronic CLE. There is an ongoing debate about the exact categorization of lupus tumidus [8*].

Descriptions of the clinical appearance of cutaneous lupus, including those resembling acne and comedones in discoid lupus, emphasize the heterogeneous clinical presentations of CLE [9*].

Two families have a well defined mutation of three prime repair exonuclease 1 (TREX1). The mutant TREX1 enzyme diminishes TREX1 function and studies suggest a role for TREX1 in double-stranded DNA (dsDNA) degradation to prevent immune activation [10**].

Oral lesions in lupus patients can be confusing. The clinical differential diagnosis of oral lupus lesions depends on whether the lesions are keratotic, ulcerated, lip lesions, erythematous purpuric macules, or bullous [11**]. For instance, ulcerated discoid lesions have a differential that includes aphthas, erosive lichen planus, traumatic ulcers, deep fungal infection, Langerhans cells histiocytosis, and squamous cell carcinoma. Biopsy of oral ulcers due to lupus show pathologic changes identical to those seen in the skin, and typically do not indicate vasculitis.

**Triggers**

There are a number of triggers of cutaneous lupus. Several recent studies have examined the low but measurable output of ultraviolet B (UVB) from compact fluorescent lights, suggesting that these should be covered in the setting of lupus patients [12*,13*]. Others have reported new medications or reviews of medications associated with subacute cutaneous lupus, including capcetabine and sertraline [14*]. Anti-TNF medications continue to be reported in association with subacute cutaneous lupus, as well as injection-site reactions from interferon-β (IFNβ) that show lupus on biopsy.

**Outcome measures**

The absence of validated outcome measures for cutaneous lupus has hampered the ability to do clinical trials or perform careful clinical cohort studies. Recent studies have expanded the initial validation of the CLASI, examining the responsiveness of the CLASI in a trial, and extending validation to rheumatology [15**,16**]. Recognition of the need for core sets of data to systematically evaluate lupus populations have been developed [17*].

**Epidemiology/organized studies**

One study examined the incidence of cutaneous lupus over a 40-year period in Olmsted County, Minnesota, and found an incidence rate of CLE of 4.3, with 19% progressing to SLE over a 20-year period [18**]. The development of a web-based database for cutaneous lupus has allowed systematic characterization of the disease severity and quality of life of cutaneous lupus patients examined in an academic center. The most therapeutically resistant patients are more likely to be smokers, confirming this risk factor for refractory disease [19*]. One study also confirmed that smoking is a risk factor for developing CLE [20*]. A systematic study of anti-Ro/SSA-positive patients with skin manifestations demonstrated that these patients do develop new autoimmune diseases and are potentially at risk of drug-induced SCLE [21*]. Pediatric discoid lupus erythematosus (DLE) is rarer, but potentially more frequently associated with SLE, particularly when generalized [22*].

**Treatment of cutaneous lupus erythematosus**

Sunscreens and sun avoidance are important aspects of treatment and prevention in CLE patients. As a result, patients frequently have low vitamin D levels and should be supplemented [23**].

There have been extraordinarily few controlled trials for cutaneous lupus. Thus, most therapy is guided by case series, case reports, and expert opinion. Topical
calcineurin inhibitors are used as adjunctive therapy [24*]. Systemic therapy for disease that is scarring, unresponsive to topical therapy, or widespread involves hydroxychloroquine at a dose of less than 6.5 mg/kg/day. For therapeutically resistant patients, there is sometimes a benefit by adding quinacrine at a dose of 50–100 mg/day. Another study of lupus erythematosus tumidus demonstrated that 61% of patients had a complete or near complete response to antimalarials, with smokers having higher initial clinical score and being less responsive to treatment [25*]. A preliminary study of two refractory CLE patients suggested that one of the patients had some improvement with lenalidomide, although its use in SLE may be problematic because of risk of immune stimulation [26*]. One open prospective study suggested that the pulsed dye laser can be effective in treating DLE [27*].

Thalidomide is an effective therapy for refractory CLE. However, there is a high incidence of sensory axonal neuropathy, the total dose of thalidomide that can cause this is relatively low, and recovery in one study occurred in 25% based on sural nerve sensory action potentials (SAP) [28*].

**Dermatomyositis**

Dermatomyositis can involve only the skin (amyopathic) or have only mild muscle findings on lab testing without clinical symptoms or signs (hypomyopathic). Pathognomonic findings include Gottron’s papules and Gottron’s sign. Characteristic findings include a heliotrope, periangual telangiectasias, dystrophic cuticles, and photodistributed violaceous erythema.

**Diagnosis**

Skin biopsies should be obtained in patients in whom dermatomyositis is in the differential, largely to determine whether the patient has an autoimmune skin disease. There is still confusion about how to diagnose amyopathic dermatomyositis, as these patients by definition do not have muscle disease and thus cannot fulfill the current criteria for dermatomyositis. Skin biopsy will not differentiate CLE from dermatomyositis, and thus clinical–pathological correlation is the key to making the diagnosis [29*].

**Triggers**

There are a number of potential drug triggers of dermatomyositis, including hydroxyurea, IFNβ1a, and TNF blockers [30*–33*].

**Outcome measures**

There have been few studies of dermatomyositis related to the skin. Hopefully, the development of validated tools will facilitate this process [34*,35*].

**Systemic sclerosis**

Cutaneous changes are common, early manifestations of SSC, important in the classification of this heterogeneous disease. The two major subtypes, limited cutaneous SSC (lcSSC) and dcSSC, are distinguished in part by the acuity and extent of cutaneous findings.

**Cutaneous outcome measures**

Skin sclerosis is one of the most common endpoints used in studying SSC; however, the relationship between sclerosis and disease morbidity and mortality is complex. A number of studies have linked the course and severity of cutaneous sclerosis with overall disease prognosis [36,37]. Rapid worsening of cutaneous sclerosis has been associated with renal crisis and reduced survival among patients with antitopoisomerase antibodies [38]. More recently, however, Shand et al. [39] applied a latent linear trajectory model to determine whether changes in modified Rodnan skin score (mRSS) are directly related to disease morbidity and mortality among dcSSC patients. Whereas the highest mortality occurred among patients with the greatest baseline mRSS who had minimal improvement over time, those with high or low baseline mRSS who subsequently improved had as many or more systemic complications as those in the highest mortality group. An analysis of 1200 patients enrolled in the German Systemic Sclerosis Network, revealed that patients with higher mRSS had a greater frequency of dysphagia, reflux, pulmonary fibrosis, digital ulcers, and joint contractures, but mRSS had no relationship with the frequency of any other systemic manifestation [40**]. Complicating matters further is the tendency of cutaneous sclerosis to improve spontaneously over time in some patients and the use of disease modifying agents that may have altered the severity of skin findings by patients in these studies.

The measurement of sclerosis also poses challenges. Although the fully validated mRSS has been considered the gold standard evaluative tool, its responsiveness has been somewhat modest in several trials, and it has been argued that it may not be sensitive enough to detect small but clinically relevant changes [41]. Additionally, the reliable administration of the mRSS requires training and experience [42]. Several other tools used include ultrasound measurement of dermal thickness, durometer, elastometer, twistometer, cutometer, and plicometer, but limitations to their use include lack of responsiveness in clinical trials, difficulty to administer or learn, poor reproducibility, or cost [43]. Recent recommendations from the Scleroderma Clinical Trial Consortium include the use of mRSS, durometer, and a visual analog scale in clinical trials of SSC [44].

**Treatments**

Therapies aimed at reducing cutaneous sclerosis are limited. Topical corticosteroids and calcineurin inhibitors
are minimally beneficial as they fail to penetrate into affected dermal tissue. Phototherapy with wavelengths in the UVA spectrum has been shown to soften skin and reduce dermal thickness in scleroderma including SSc [45,46,47•]. Systemic immunosuppressive agents including corticosteroids, methotrexate, cyclophosphamide, and cyclosporine have been used with varying success to improve sclerosis. The role of d-penicillamine has been controversial, with benefits reported in open and retrospective trials [36,48] but with no difference demonstrated in a double-blind randomized controlled trial comparing high and low dosages [49]. A recent trial of mycophenolate mofetil combined with intravenous and oral corticosteroids demonstrated improvement in mRSS [50]. Conflicting results have been reported in two recent small trials of the anti-CD20 molecule, rituximab, with improvement in mRSS reported in one study [51], but not the other [52]. A lack of efficacy and an increased morbidity and/or mortality have been reported from trials of recombinant relaxin [53] and a recombinant anti-tissue growth factor β1 (TGFβ1) antibody [54].

In addition to sclerosis, vascular disorder contributes to cutaneous manifestations of sclerodema including Raynaud’s phenomenon and digital ulceration. Treatment remains challenging. Intravenous iloprost is approved for the treatment of severe Raynaud’s phenomenon with ulcerations, and a recent open-label randomized trial demonstrated equal efficacy of low and high dose iloprost [55•]. In Europe, the endothelin receptor antagonist, bosentan, has been approved for prevention of digital ulcers. To better predict those at risk for digital ulcers, Sebastiani et al. [56] utilized nailfold videocapillaroscopic data to create a mathematical model capable of predicting digital ulcers with a sensitivity of 85.9% and specificity of 94.3%.

Insights into the pathogenesis of SSc have led to potential novel therapeutics. Inhibition of histone deacetylase-7 in vitro led to decreased type I and III collagen synthesis; this enzyme may be a potential therapeutic target in SSc [57]. The stimulatory effects of TGFβ on extracellular matrix synthesis are mediated by connective TGF (CTGF). Administration of an anti-CTGF antibody inhibited TGFβ-induced fibrosis in a murine model of fibrosis [58]. Finally, closer yet to bedside are tyrosine kinase inhibitors such as imatinib. By inhibiting platelet-derived growth factor receptor (PDGFR) signaling, they reduce cutaneous and systemic fibrosis as demonstrated by in-vitro, animal, and human data [59••,60]. Clinical trials of imatinib for SSc are ongoing.

Rheumatoid arthritis
The pathmechanisms of the cutaneous manifestations of RA including rheumatoid nodules, granulomatous dermatoses, and rheumatoid vasculitis are unknown; however, immune complex deposition and/or small vessel vasculitis are likely important.

Rheumatoid nodules
Rheumatoid nodules are the most common extra-articular manifestation of RA and occur in 20–30% of affected individuals. They are more common in men and in those with rheumatoid factor seropositivity. They appear as flesh-colored, firm, subcutaneous nodules that range in size from millimeters to several centimeters. They are usually painless and often occur over extensor surfaces or at sites of repetitive stress. Nodules may shrink, persist, or worsen with RA treatment. Accelerated nodulosis, characterized by the abrupt onset or worsening of rheumatoid nodules, has been described following therapy with leflunomide [61], methotrexate, TNF-inhibitors, and with an aromatase inhibitor for breast cancer in a patient with RA [62].

Rheumatoid vasculitis
The skin is involved in 75–89% of patients with rheumatoid vasculitis, often as the presenting sign of the condition [63]. Purpura, livedo reticularis, atrophic blanche, and ulcers are cutaneous signs of rheumatoid vasculitis. It is associated with longstanding, erosive, seropositive disease, and is more frequent in those with antibodies to citrullinated peptides [64••]. TNF-inhibitor therapy has been associated both with onset and improvement of rheumatoid vasculitis [64••,65]. Treatment with argatroban, an antithrombin agent, in a patient with antiphosphatidylserine–prothrombin complex antibodies led to resolution of ulcers refractory to immunosuppressive therapy [66].

Granulomatous dermatitis
Interstitial granulomatous dermatitis (IGD) and palisaded neutrophilic and granulomatous dermatitis (PNGD) are eruptions associated with autoimmune diseases including RA. These eruptions represent reaction patterns related to cutaneous immune complex deposition [67]. The polymorphous eruption of IGD favors the trunk, thighs, and axillae in a symmetric fashion and is characterized by erythematous, indurated, linear bands, papules, nodules, or annular plaques. PNGD is characterized by symmetric papules and nodules on the extremities. Spontaneous resolution is common, but treatments including NSAIDS, prednisone, dapsone, colchicine, oral tacrolimus [68], and TNF-inhibitors [69] have been reported. TNF-inhibitors have also been linked to onset of the eruption [70,71].

Psoriasiform eruptions related to tumor necrosis factor α inhibitor therapies
Patients treated with TNFα inhibitors may develop an eruption that is clinically and histologically indistinguishable from psoriasis. This can occur in those receiving these agents for any condition; although those with RA
appear to be at greatest risk. The eruption typically clears with drug cessation, and may or may not recur during treatment with other drugs of this class [72–74].

Conclusion
Skin manifestations are often prominent or at times sole features of lupus erythematosus, dermatomyositis, SSc, and RA. The easy observability and accessibility of the skin for study has and will continue to enhance our understanding of the pathogenesis of these systemic diseases. The development of validated outcome measures is imperative for reliably objectifying the cutaneous manifestations of these diseases and their response to therapeutic interventions. Patient databases and multidisciplinary collaboration will enable the performance of larger and more meaningful clinical trials.

Acknowledgement
The present study was supported by NIH K24-AR 02207 and a V.A. Merit Review Grant.

References and recommended reading
Papers of particular interest, published within the annual period of review, have been highlighted as:
• of special interest
•• of outstanding interest
Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 103–104).

8 Callen JP. Clinically relevant information about cutaneous lupus erythema-
•• Excellent overview of current clinical research issues related to cutaneous lupus.
9 Hemmati I, Otberg N, Martinka M, et al. Discoid lupus erythematosus pre-
•• Report that emphasizes the variation in presentations of discoid lupus.
10 Lehtinen DA, Harvey S, Mulcahy MJ, et al. The TREX1 double-stranded DNA
•• Studies that support a direct role for TREX1 in the degradation of dsDNA to prevent autoimmune disease. TREX1 mutations have been determined in familial chilblain lupus.
11 Nico MM, Vilela MA, Rivitti EA, Lourenco SV. Oral lesions in lupus erythe-
•• Excellent overview of clinical and pathologic findings in oral lesions in lupus erythematosus, emphasizing the importance of differential diagnosis and lack of correlation with vasculitis.
12 Nuzum-Keim AD, Sontheimer RD. Ultraviolet light output of compact fluor-
•• escent lamps: comparison to conventional incandescent and halogen resis-
•• This study measures the output of different types of light bulbs and determines that compact fluorescent bulbs have less emission when covered.
13 Klein RS, Worth VP, Dowdy JC, Sayre RM. Analysis of compact fluorescent
•• There are variable amounts of ultraviolet light emitted from compact fluorescent lights, a number of which are tested in this study.
14 Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cuta-
•• neous lupus erythematosus: a paradigm for bedside-to-bench patient-orien-
•• Comprehensive review article about history and drugs implicated in drug-induced SCLE.
15 Bonilla-Martinez Z, Albrecht J, Taylor L, et al. The CLASI is a useful
••• This is a study that demonstrates the responsiveness of the CLASI, an important study for extending validation of this index for measuring cutaneous lupus activity and damage.
16 Krathen MS, Dunham J, Gaines E, et al. The Cutaneous Lupus Erythematosus
••• An important study that extends validation of the CLASI to rheumatologists.
••• Development of a Core Set Questionnaire for CLE for the European Society of Cutaneous Lupus Erythematosus.
18 Duraooso O, Davis MD, Reid KB, Rohlinger AL. Incidence of cutaneous lupus
••• This is the first population-based study related to the incidence of cutaneous lupus.
•••• This is the first systematic prospective study of the subtypes and severity of cutaneous lupus seen in an academic referral center.
20 Koskenmies S, Janvren TM, Ohkamo P, et al. Clinical and laboratory charac-
••••• teristics of Finnish lupus erythematosus patients with cutaneous manifesta-
••••• Careful evaluation of 178 cutaneous lupus patients in terms of subsets, cluster analysis, laboratory findings, and increased smoking at disease onset relative to the general population.
21 Popovic K, Wahren-Herlenius M, Nyberg F. Clinical follow-up of 102 anti-Ro/
••••• SSA-positive patients with dermatological manifestations. Acta Derm Vener-
••••• eol 2008; 88:370–375.
••••• This is a study that reports development of a number of different autoimmune diseases in cohorts of patients who are Ro/SSA-positive.
22 Sampaio MC, de Oliveira ZN, Machado MC, et al. Discoid lupus erythema-
••••• This is a relatively large retrospective cohort of 34 children with discoid lupus.
23 Cusack C, Danby C, Fallon JC, et al. Photoprotective behaviour and sunsc-
••••• This study examines the vitamin D levels in 52 patients with cutaneous lupus determines that many have low vitamin D levels.
24 Tzilloa TG, Kougelas D. Topical tacrolimus and pimecrolimus in the treatment
••••• This is a review of the five studies performed to evaluate the efficacy of topical macrolides for treatment of cutaneous lupus.
••••• This is a study that systematically evaluates the efficacy of antimalarials in tumid lupus, also demonstrating a decreased effect in smokers.
••••• Report of two cases of resistant discoid lupus treated with the thalidomide derivative lenalidomide, one of whom partially improved.
Rheumatic manifestations of skin disease Clarke and Werth 83


This retrospective study is one of the few documenting the generally accepted effectiveness of phototherapy for cutaneous disease in diffuse and localized scleroderma.


This prospective, open-label, randomized trial demonstrates the equivalent efficacy of low-dose and high-dose iloprost for severe Raynaud’s phenomenon.


58 Ikawa Y, Ng PS, Endo K, et al. Neutralizing monoclonal antibody to human connective tissue growth factor ameliorates transforming growth factor-beta-


This is one of the first studies demonstrating clinical efficacy of imatinib mesylate in two patients with diffuse cutaneous SSCs. The results of immunohistochemical analyses of skin biopsy specimens and gene expression profiling in these patients suggested that PDGFβR and Abi play critical, synergistic roles in the pathogenesis of SSCs, and that imatinib targets a gene expression program that is frequently dysregulated in SSC.


63 Sayah A, English JC. Rheumatoid arthritis: a review of the cutaneous mani-


64 Turesson C, Mattsson EL. Vasculitis in rheumatoid arthritis. Curr Opin


This current review explores the pathophysiology, epidemiology, clinical features, and therapeutic options related to rheumatoid vasculitis.

Systemic disorders with rheumatic manifestations